The proinflammatory cytokines have been shown to increase cellular tight-junction permeability [52–54] and mucosal inflammation in IBD patients [55], thus restoring intestinal permeability in response to anti-TNF therapy [56,57]. This evidence concerns the gene TNF and inflammatory bowel disease.